Format

Send to

Choose Destination
Nat Rev Immunol. 2002 Aug;2(8):615-21.

Gene therapy of severe combined immunodeficiencies.

Author information

1
INSERM U429, Hôpital Necker, 149 rue de Sèvres, 75015 Paris, France. fischer@necker.fr

Abstract

The concept that the outcome of a devastating disease can be modified by inserting a transgene into abnormal cells is appealing. However, the gene-transfer technologies that are available at present have limited the success of gene therapy so far. Nevertheless, severe combined immunodeficiencies are a useful model, because gene transfer can confer a selective advantage to transduced cells. In this way, a proof of concept for gene therapy has been provided.

PMID:
12154380
DOI:
10.1038/nri859
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center